Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment for patients with advanced or recurrent endometrial carcinoma.
The trial included patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair proficient (pMMR)/not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)/MSI-H.
Also Read: Full story available on Benzinga.com